Grafalon

Grafalon is a rabbit-derived anti‑thymocyte globulin formulated as an injectable solution for intravenous administration. The active ingredient, anti‑T lymphocyte immunoglobulin for human use, provides a polyclonal antibody preparation that targets T‑lymphocytes. It is supplied in the European market as a prescription‑only immunosuppressive agent and is used under medical supervision for specific transplant and hematologic indications. It is administered by healthcare professionals in controlled settings to achieve profound immunosuppression.

Grafalon is indicated for specific clinical situations where strong immunosuppression is required.

- Prevention of acute rejection in solid organ transplantation (e.g., kidney, liver, heart). - Induction therapy in bone marrow or stem cell transplantation to reduce graft‑versus‑host disease. - Treatment of severe aplastic anemia when other therapies are insufficient. - Use as part of conditioning regimens prior to hematopoietic stem cell transplantation.

The immunologic activity of Grafalon can produce a range of adverse effects, which are generally categorized by frequency and severity.

Common: - Fever and chills - Rash or urticaria - Nausea or vomiting - Hypotension during infusion - Headache - Arthralgia or muscle aches

Serious: - Serum sickness-like reactions - Severe infections (bacterial, viral, fungal) - Pulmonary edema or respiratory distress - Renal dysfunction or failure - Cytokine release syndrome - Hemolytic anemia or thrombocytopenia

Because Grafalon causes profound depletion of T‑cells, careful patient assessment and monitoring are essential before and during therapy.

- Assess for active infections and treat before initiation. - Evaluate baseline liver and kidney function. - Monitor complete blood count and immunoglobulin levels regularly. - Use prophylactic antimicrobials to reduce opportunistic infection risk. - Avoid use in patients with known hypersensitivity to rabbit proteins. - Consider pregnancy and breastfeeding status; limited data are available.

Grafalon may interact with other agents that affect immune function or increase the risk of adverse reactions.

Avoid: - Concomitant use of other potent immunosuppressants without dose adjustment. - Live vaccines during treatment and for several weeks after. - High‑dose corticosteroids that may exacerbate infection risk.

Use with caution: - Antimicrobial agents (e.g., antifungals, antivirals) that may require dose modification. - Cytokine‑targeted therapies such as IL‑2 or interferon. - Drugs that prolong QT interval, as electrolyte disturbances can occur.